Sentences with phrase «objective response rate»

Patients whose tumors had a normal BRAF gene showed an overall objective response rate of 61 %.

The biotech specialist said that its updated phase 2 data in a study of its poziotinib candidate treatment for non-small cell lung cancer resulted in a preliminary confirmed objective response rate and potential progression - free survival benefit in patients with the EGFR Exon 20 Mutant form of the disease.

With nivolumab monotherapy, the observed objective response rate was 23.3 % in the mucosal melanoma group compared with 40.9 % in the cutaneous melanoma group.

Data from these two trials also showed an objective response rate of 72 percent among the 18 patients who met criteria for what was defined as a phase II - eligible population.

«Although still only in an early phase trial, brigatinib is showing an objective response rate in approximately 70 percent of ALK - positive patients post-crizotinib and it's showing about a year of progression - free survival.

The objective response rate (defined as the proportion of complete response and partial responses among all evaluable patients) was also higher with chemotherapy (92/549, 16.8 percent) compared with TKI (39/540, 7.2 percent).

In addition to helping patients live longer, more patients treated with pembrolizumab responded to treatment and for a longer duration than those treated with chemotherapy; the objective response rate — the percentage of patients whose tumours shrank or disappeared — was almost twice as high with pembrolizumab: 21 % compared to 11 % on chemotherapy.

The objective response rate, the primary endpoint for the study, was 16 percent (3 of 19).

In the pooled analysis, the objective response rate was 11 % for nivolumab and 22 % for nivolumab plus ipilimumab.

The objective response rate for the combination was 23 %; for nivolumab monotherapy, it was 11 %.

The objective response rate was 37.1 % and 60.4 % in the mucosal and cutaneous melanoma groups, respectively, and median progression - free survival was 5.9 months vs 11.7 months.

Previously, nivolumab plus ipilimumab had improved progression - free survival (PFS) and objective response rate (ORR) vs ipilimumab alone in the phase II CheckMate 069 and phase III CheckMate 067 trials of treatment - naive patients with advanced melanoma.

Although lack of effectiveness in the advanced setting does not preclude efficacy in the adjuvant setting, our retrospective single - center study of advanced mucosal melanoma yielded an objective response rate of only 10 % to alkylator - based cytotoxic therapy, suggesting a general lack of efficacy for chemotherapy in this disease.

A study of this combination showed that trametinib / dabrafenib resulted in an objective response rate of 76 % compared with 54 % in patients treated with the BRAF inhibitor alone.

Patients receiving the combination had an objective response rate of 50 %, compared to 40 % for nivolumab and 14 % for ipilimumab — an increase greater than either drug alone.

Interim phase II results [12] of first treatment with electroporation of IL - 12 in 28 patients with advanced melanoma, after 24 weeks of treatment, reported at the American Society of Clinical Oncology 2014 Annual Meeting, revealed a 32.2 % objective response rate (ORR; the primary endpoint), with a CR in 10.7 %.

The objective response rate to the therapy was 22 %, with a slightly higher response rate (23 % vs 15 %) among those on a weekly dosing schedule than those on an every -3-weeks schedule.